COLL

AI Memo

Collegium Pharmaceutical

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 earnings established ADHD momentum but exposed pain-franchise pressure • 2026-08-06

Base target: $27 / p=50% prob

Biggest risk

The Q2 revenue result reportedly missed consensus despite an adjusted-EPS beat, while NUCYNTA pricing pressure and weaker-than-expected EBITDA guidance create execution and margin risks. Analyst revisions and target changes are unavailable.

Invalidation

Break below $18 or thesis failure.

What would change my mind?

JORNAY PM growth, AZSTARYS contribution, expanded ADHD commercial coverage, and a higher reported full-year revenue guidance midpoint could support a rerating if back-to-school demand validates the portfolio strategy.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-02

Base target

$27

p=50%

Bull target

$34

p=25%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Back-to-school ADHD execution
AZSTARYS integration and commercial uptake
JORNAY PM growth, AZSTARYS contribution, expanded ADHD commercial coverage, and a higher reported full-year revenue guidance midpoint could support a rerating if back-to-school demand validates the portfolio strategy.

BearKey bullets

AZSTARYS integration and demand conversion remain early-stage after the acquisition.
Back-to-school prescription growth may not meet expectations for JORNAY PM and AZSTARYS.
NUCYNTA authorized-generic pricing pressure may continue to weigh on the pain franchise.

WatchKey bullets

Q2 earnings established ADHD momentum but exposed pain-franchise pressure

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $27 (p=50%)

Target spread vs base: +26% / -33%

Scenario probabilities

Bull Target: $34 (p=25%)Base Target: $27 (p=50%)Bear Target: $18 (p=25%)

Commentary

News coverage is concentrated on the Q2 earnings print. Stored secondary earnings context describes a negative market reaction despite an adjusted-EPS beat and higher revenue guidance, while verified analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable. The evidence supports a tentative-positive monitoring view rather than a high-conviction rerating thesis.

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Back-to-school ADHD execution
AZSTARYS integration and commercial uptake

Scenarios

Bull Target (Scenario probability)

$34 / p=25% prob

Base Target (Scenario probability)

$27 / p=50% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 earnings established ADHD momentum but exposed pain-franchise pressure
Q2 net revenue rose 6% year over year to $199.9 million; JORNAY PM revenue rose 41% to $46.1 million and AZSTARYS contributed $12.9 million after acquisition. Management said the expanded ADHD salesforce was deployed ahead of back-to-school season, while NUCYNTA faced increased pressure. [#SEC-8K-2026-08-06]
Prob 95.00% • Move 0.00% • Priced-in 100.00%
EVENT2026-12-31
ASR final settlement
The final settlement of the accelerated share repurchase agreement is expected no later than Q4 2026, providing a defined capital-allocation checkpoint. [#8-K-2026-08-13]
Prob 80.00% • Move 3.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Back-to-school ADHD execution
2026-09-30
The key near-term test is prescription and prescriber momentum for JORNAY PM and AZSTARYS as the expanded commercial organization enters the back-to-school period. [#SEC-8K-2026-08-06]
Prob 65% • Move 8% • Priced-in 55%

Long-term Catalysts

Months to a year

AZSTARYS integration and commercial uptake
2027-12-31
AZSTARYS adds a complementary ADHD medicine with expected patent protection through 2037. Sustained uptake and successful integration could extend Collegium's growth profile, but execution remains unproven. [#SEC-8K-2026-08-06]
Prob 55% • Move 18% • Priced-in 50%

Risks

AZSTARYS integration and demand conversion remain early-stage after the acquisition.
Back-to-school prescription growth may not meet expectations for JORNAY PM and AZSTARYS.
NUCYNTA authorized-generic pricing pressure may continue to weigh on the pain franchise.
Potential generic entry risk for Belbuca in 2027 was noted in stored secondary earnings context.
Stored secondary earnings context reports EBITDA guidance below analyst expectations and margin pressure; verified analyst revision data is unavailable.

Peers

Symbol	Summary
AMPH	Same-sector, similar-market-cap commercial pharmaceutical candidate; the packet does not establish direct ADHD or pain-portfolio overlap.
ABUS	Same-sector, similar-market-cap biotechnology candidate; useful only as broad sector context and not a close operating comparable.
CADL	Same-sector, similar-market-cap biotechnology candidate; the packet provides no direct commercial or therapeutic comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

AMPH

Same-sector, similar-market-cap commercial pharmaceutical candidate; the packet does not establish direct ADHD or pain-portfolio overlap.

ABUS

Same-sector, similar-market-cap biotechnology candidate; useful only as broad sector context and not a close operating comparable.

CADL

Same-sector, similar-market-cap biotechnology candidate; the packet provides no direct commercial or therapeutic comparability.